Use cases for LASV diagnostics: needs based on target use and setting in a Lassa-affected country
| Intended use case | Target use setting/diagnostic needs | ||||
| 4 | 3 | 2 | 1 | 0 | |
| National reference lab | Referral/regional hospital | District hospitals | Health centres | Health posts, field settings | |
| Case detection and management | MDx*† POC MDx*† IA*† | MDx*† POC MDx*† IA* | POC MDx* POC IA* RDT* | ||
| Surveillance | MDx*† sequencing IA* | MDx* POC MDx* IA* | POC MDx* POC IA* RDT* | RDT* | |
| Outbreak response | MDx*† POC MDx*† sequencing IA* | MDx* POC MDx* IA* | POC MDx*
POC IA* RDT* | RDT* | RDT* |
| Clinical trials (vaccine, therapeutics) | MDx*† POC MDx*† sequencing IA*† | MDx*† POC MDx*† IA*† | POC MDx* POC IA* | ||
*Requires pan-LASV detection.
†Requires pan-VHF differentiation.
IA, immunoassay (eg, ELISA); LASV, Lassa virus; MDx, molecular diagnostics (eg, reverse transcriptase PCR); POC, point-of-care or near-patient; RDT, rapid diagnostic test (eg, lateral flow immunoassay); VHF, Viral haemorrhagic fever.